Market research
VRNA Verona Pharma PLC ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9B
- P/E ratio
- Not available
- Analyst target
- 106
- Dividend yield
- Not available
- Beta
- 0.05
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US9250501064
- Market cap
- 9B
- P/E ratio
- Not available
- Analyst target
- 106
- Dividend yield
- Not available
- Beta
- 0.05
About
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VRNA discussion.
5 years, 4 months ago
Verona Pharma plc is currently in a long term downtrend where the price is trading 21.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Verona Pharma plc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.1% to $-65K since the same quarter in the previous year.
Finally, its free cash flow grew by 99.9% to $-9K since the same quarter in the previous year.
Based on the above factors, Verona Pharma plc gets an overall score of 3/5.